Korsana Biosciences, Inc. filed a Form 8-K on November 19, 2026, disclosing that shareholders voted at a November 13, 2026 special meeting to approve the company's redomestication from Massachusetts to the Cayman Islands.
Key Highlights
- Special meeting held online: The special meeting took place exclusively via live webcast on November 13, 2026.
- Record date shares: As of October 7, 2026, 45,541,358 shares were issued, outstanding, and entitled to vote.
- Quorum reached: 40,022,552 shares were present or represented by proxy, constituting a quorum.
- Domestication Proposal approved: Proposal No. 1 received 36,182,762 votes for and 3,839,724 votes against, with 67 abstentions and no broker non-votes.
- Continuation and Cayman Articles Proposal approved: Proposal No. 2 received 36,183,829 votes for and 3,838,657 votes against, with 67 abstentions and no broker non-votes.
- Adjournment not needed: Proposal No. 3, an adjournment proposal, was determined to be unnecessary as sufficient votes were secured for both redomestication proposals.
Korsana Biosciences Shareholder Vote on Massachusetts-to-Cayman Redomestication
According to the filing, Korsana Biosciences, Inc. (NASDAQ:KRSA), incorporated in Massachusetts and headquartered at 203 Crescent Street, Waltham, Massachusetts, held a special meeting of shareholders on November 13, 2026, conducted entirely online via live webcast. The company disclosed that the record date for determining eligible voters was October 7, 2026, at which time 45,541,358 shares of common stock were issued, outstanding, and entitled to vote. A total of 40,022,552 shares were present or represented by proxy at the meeting, the filing stated, constituting a quorum.
The filing reported that shareholders voted on two proposals collectively referred to as the "Redomestication Proposal," each described in greater detail in the company's definitive proxy statement filed with the Securities and Exchange Commission on October 15, 2026. Proposal No. 1, the "Domestication Proposal," sought approval under the Massachusetts Business Corporation Act for the company's redomestication to an exempted company incorporated under the laws of the Cayman Islands by domestication pursuant to Section 9.20 of the Massachusetts Business Corporation Act. Shareholders approved this proposal with 36,182,762 votes for, 3,839,724 votes against, 67 abstentions, and no broker non-votes, according to the filing.
Proposal No. 2, the "Continuation and Cayman Articles Proposal," sought approval under the Companies Act (As Revised) of the Cayman Islands for redomestication by way of continuation, and also sought adoption, as a special resolution under Cayman Islands law, of the company's memorandum and articles of association. The filing reported that this proposal received 36,183,829 votes for, 3,838,657 votes against, 67 abstentions, and no broker non-votes. The filing further disclosed that an adjournment proposal was solicited but deemed unnecessary because sufficient votes had been secured for both redomestication proposals. The 8-K was signed by Mark Vignola, Ph.D., Chief Financial Officer.
What Was Disclosed
Korsana Biosciences disclosed the voting results from its November 13, 2026 special shareholder meeting, at which shareholders approved both proposals authorizing the company's redomestication from Massachusetts to the Cayman Islands.



Please wait processing your request...